Evidence of Durable Single Agent Activity and Immune Response of MDNA11 in ABILITY-1 Study
Friday, 31 May 2024, 10:40
Evidence of Durable Single Agent Activity
Medicenna recently showcased the remarkable performance of MDNA11 as a single agent.
Potent Immune Effector Response
The ABILITY-1 study revealed a strong immune response triggered by MDNA11.
This development at the 10th Annual Oncology Conference signifies a significant step forward in cancer treatment research, with MDNA11 showing promise in delivering positive outcomes.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.